“Safety and Efficacy Study Evaluating TRx0237 in Subjects with Behavioral Variant FTD”: On May 16 at Beacon Pointe Memory Care Community, 1 Emma Lane, Clifton Park, NY, Dr. Richard Holub, a neurologist in Albany, NY with 25 years’ experience with FTD and related dementias, will present information on an upcoming clinical trial evaluating the drug TRx0237 in people with bvFTD at 7 p.m.  Learn more about the drug and its possible effects, eligibility for participation and more.  For more information contact Lauren Jacobi, Beacon Pointe Marketing Director at 518-371-2200.